INTRODUCTION
The neonatal screening (NBS) program in the Netherlands is a nationwide universal screening program, offered to all newborns. Peripheral blood is collected by heel prick shortly after birth and preserved as a dried blood spot on a filter paper (Guthrie spot). The uptake of neonatal screening in the Netherlands is high: in 2008 a heel prick was performed in 99.8% of all newborns. 1 It is estimated that at least 1.6 million immigrants from different populations at-risk for SCD are living in the Netherlands and that ~10% are carriers of hemoglobinopathy. 2, 3 It is known that early identification and treatment of children with SCD result in a decrease in morbidity and mortality. 4, 5 but not all provide universal neonatal screening. [6] [7] [8] The benefit of reporting SCD carriers at this stage consists of prospective detection of couples at risk, who can then be informed about future reproductive choices. 9, 10 It has been suggested that genetic information will enable couples to make informed decisions about diagnostic testing and/or termination of future affected pregnancies. Potential disadvantages of reporting carriers could be related to anxiety and distress from being given an unexpected and "abnormal" test-result, and to potential misunderstandings of the risk-information. Other disadvantages may be the burden of potential stigmatization and discrimination imposed on carriers, worrying about the carrier child, and revelation of non-paternity. 9 To avoid unwanted confrontation, parents in the Netherlands are offered, starting in 2011, the possibility of 'opting out' at the moment of the heelprick, where they can indicate that they do not want to be informed on the carrier state in their newborn.
ABSTRACT Purpose
In 2007, the neonatal screening program in the Netherlands was expanded to include hemoglobinopathies. Newborns with sickle cell disease (SCD), as well as SCD carriers are identified. The benefit of reporting SCD carriers includes detection of more couples at risk (both parents are carriers) who can be informed about future reproductive choices, a responsibility of their general practitioner (GP). We evaluated knowledge, ideas and actions of GPs after reporting SCD carriers and explored and analyzed potential barriers.
Methods
A questionnaire study.
Results
A total of 139 GPs responded to our questionnaire (49%). 90 GPs (90%) stated they informed parents of the test result. In only 23 cases (23%) both parents had themselves tested for hemoglobinopathies. 81 GPs (64%) stated they did not have enough clinical experience with SCD. Almost half of the GPs indicated they did not experience any barriers in counseling patients (n=60, 48%).
Conclusion
At the moment the goal of the neonatal screening for SCD carriers has not been achieved as the majority of parents were not tested for hemoglobinopathies after disclosure of carrier status in their newborn. With GPs reporting few barriers in counseling parents and only indicating a lack of knowledge and clinical experience, more effort is required to provide better information to GPs to help facilitate their work.
In May 2009 we sent all selected GPs a questionnaire with an introductory letter and a stamped return envelope. GPs were kindly asked to complete the questionnaire and to return it. After three weeks a reminder was sent to all nonresponders and after an additional four weeks a second reminder was sent, with a second copy of the questionnaire and a stamped return envelope. The inquiry was closed eight weeks after the last reminder was sent.
Questionnaire
The questionnaire had four sections and took about ten minutes to complete. Most questions were in a multiple choice format. The first section contained questions on GP demographics: 
Analysis
All data were entered in a database and analyzed anonymously. GP demographics were summarized and compared between high and low prevalence areas. We defined the area with the highest prevalence of population at risk, being the southeast part of Amsterdam. The number of correct answers and the number of items discussed per GP were counted.
Differences between subgroups were tested with the Student's t test and ANOVA test for parametric continuous variables, the Mann-Whitney U test or Kruskal Wallis test for nonWhen a carrier is identified, parents receive a letter explaining the test result. Additionally, two weeks after the letter to the parents, their GP receives written information. GPs are advised to contact the parents to communicate the test result, to provide genetic information about the meaning of the test, to emphasize the importance of testing both parents for hemoglobinopathy and, finally, to refer couples at-risk to a clinical geneticist.
For the successful disclosure of information, it is essential that GPs perform these tasks adequately. Since this is the first time that carriers of a genetic trait are reported in a nationwide screening program, this is a new challenge for Dutch GPs. Previous studies reported that GPs in general are willing to integrate genetics into clinical care, but that they may be cautious about moving beyond their traditional role.
11,12
During the first year (2007), 182.303 newborns were tested and 806 SCD carriers were found (0.4%), of which 478 (59%) were born in the western part of the country, in and around
Rotterdam and Amsterdam. Based on data from two Clinical cenetics Centers in Academic
Hospitals in Rotterdam and Amsterdam, in 2007 not a single couple at risk was referred after disclosure of carrier ship of SCD in their newborn, in contrast to all children who were found to have SCD. 13, 14 To understand the reasons of this failure, we sent a questionnaire to GPs in the Amsterdam region. The main objectives of this study were a) to evaluate compliance of the GPs to the NBS program according to the instructions given by letter, b) to assess the knowledge about hemoglobinopathies, and c) to explore the potential risks and benefits of disclosing carriers of SCD reported by GPs.
MATERIALS AND METHODS

Study, population and design
For this study we used a subset of the national laboratory database (RIVM) which contains information on all newborns in the high prevalence northwest region of the Netherlands were considered to indicate statistical significance. All statistical analyses were performed using SPSS version 16.0.
RESULTS
We identified 285 GPs to whom newborn carriers of SCD were reported. Consequently, a questionnaire was sent to all of them. In total, 139 GPs responded (49%) and 131 questionnaires were eligible for data-analysis, 8 questionnaires were returned blank.
Demographic and practice characteristics.
GP characteristics are summarized in Table 1 . Almost all were of North European origin (n=121, 92%) and 19 had a practice in the high prevalence region southeast Amsterdam (15%).
Most GPs in this area (n=13/19, 68%), reported that at least 41% of their practice consisted of patients from at risk populations for SCD.
Knowledge about SCD and carrier status
Most participants (n=124; 95%) answered correctly that both parents have to be a carrier to be at risk for a child with SCD. However, only 64% (n=79 out of 124) stated correctly that this risk was 25% for each pregnancy. Only 15% (n=19 out of 131) was aware of the primary goal of reporting carriers being 'to guide reproductive decisions of parents'. GPs in South-East Amsterdam answered significant more questions correctly than GPs in other areas (p=0.03). The mean number of correctly answered questions was 3 out of 6 (SD 0.98). There were no significant statistic differences in the number of correctly answered questions in subgroups defined by gender or age. Informing parents of the result of the test In our data set, 100 GPs (76%) indicated they could remember being informed about a newborn carrier of SCD in their practice. Of those 100, 90 (90%) stated that they did inform parents of this result. Information was given to either the mother (n=43, 43%) or to both parents (n=39, 39%). After informing parents, 23 GPs referred immediately, without testing the parents first, to either a pediatrician (n=15) or to a clinical geneticist (n=8). None of the referred couples turned out to be a couple at risk. Table 2 summarizes the items discussed during the consultation. 13 GPs stated they discussed all items (13%), 10 stated they discussed none (10%). Female GPs discussed more items than male GPs (p=0.02). The median number of items discussed was 6 (IQR 3 to 7). There was no difference in the number of items discussed between GPs in the high prevalence area and in other areas (p=0.16). We observed a positive and significant correlation between the number of correctly answered questions and the number of items discussed (Pearson r: 0.21, p=0.04). Steps taken by parents
We asked the GP which actions were undertaken by parents after being informed about their risk to be a carrier. About a third of GPs did not know which (if any) steps were taken by the parents. In 23 cases, both parents were tested (23%), in 17 cases only the mother was tested (17%) and in 3 cases only father was tested (3%). In 15 cases parents had siblings of the newborn tested (15%). Two GPs indicated that the test results revealed a couple at risk. None of these couples were referred.
Reported barriers in counseling parents
We classified the statements into intrinsic and extrinsic barriers ( Table 3 ). The most reported intrinsic barrier was 'I do not have enough clinical experience with sickle cell disease' (n=81, 64%).
The most reported extrinsic barrier was 'Sickle cell disease and sickle cell trait are too rare in my practice' (n=58, 46%). There was a high correlation between GPs indicating a lack of clinical experience and indicating that SCD was too rare in their practice (Spearman 0.49, p<0.001).
Almost half of the GPs stated they did not experience any barriers in counseling patients (n=60, 48%).
GPs in the high prevalence area agreed more often with the statement that they did not experience barriers in counseling patients (74%), compared to GPs in the other areas (43%) (p=0.02).
Statements about disclosing carrier status
Most GPs stated they did not think that reporting carrier status for hemoglobinopathies will lead to adverse consequences. Almost two-thirds agreed with the statement that informing parents of SCD carrier status will influence their reproductive choices (n=81, 65%). A large majority did not think that testing for SCD could lead to discrimination (n=107, 86%). More than three-quarters felt that providing risk information and counseling is a task for GPs (n=97, 78%). 
DISCUSSION
Universal neonatal screening for hemoglobinopathies was introduced in the Netherlands in 2007. Our study shows that disclosure of carriers of SCD in the first year led in only a small percentage to consecutive testing of parents for hemoglobinopathy. In our data set only a quarter of the informed parents (both partners) were tested. Although we realize that these results are only based on the first two years of the introduction of carrier screening, the results of this study should not be ignored and can be taken into account to improve the communication of disclosing carrier status.
In the Netherlands, the GP is supposed to inform parents of the carrier status of SCD found in the NBS, where, in other countries, more specialized health care providers are available. 8, 15, 16 Most GPs in our study did not report barriers in counseling parents and in providing risk information, even though the majority admitted they lacked specific clinical experience and knowledge about the disease and its inheritance. However, a great variation in the knowledge of GPs was evident, regarding the information they provided and the steps they took. GPs in the high prevalence area, with more clinical experience, knew more about hemoglobinopathy.
Studies in other countries have reported similar results.
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There are a few limitations to this study which should be addressed. First, our response rate was 49% which could have lead to a possible selection bias. Since we have no data on the non-responders, it is possible that a large part of the non-responding GPs actually did not inform parents. In that case our results are overestimated and the percentage of parents tested consecutively for hemoglobinopathies falls to 12%. Secondly, this study only focused on the perception, attitudes and actions of the GPs. We did not approach the parents and it is therefore unknown which information is provided to the parents during the consultation with the GP and how parents interpreted this. Thirdly, our survey was held in May 2009, which could have led to a recall bias. For some of the GPs it was two years ago that they were informed of the result of the carrier status and they might not have remembered exactly what they said to parents or what steps the parents took as a result.
Although it remains partially unclear why the goal of reporting carriers of SCD in the NBS is not met at this moment, we may consider a few essential facts. Since only 15% of the GPs in our study knew that the primary goal of reporting carriers was to identify couples at risk and to guide reproductive decisions of parents, it is likely that parents were not encouraged to undergo testing themselves when left alone to take this decision. Other studies have also reported a lack of knowledge among GPs about SCD, SCT and genetics in general. 18, 19 Other authors have also recommended that awareness of the goal of reporting carriers and knowledge about SCD must be improved. 17 To facilitate this more information should be provided by organizing regional education meetings and by sending written information with the results of the NBS.
For example a step-by-step guide could be sent to GPs, together with the test result, telling
them more precisely what to do, and what to tell parents. A particular challenge may be GPs who report no barriers in counseling parents, as they may be less inclined to change their routine, since they feel there are no difficulties.
Attention should also be given to the specific social and cultural characteristics of the population at risk for SCD. Being unfamiliar with the severity of the disease and the hereditary aspects may compromise reproductive decisions after disclosure of carrier status. Moreover, parents may disregard the advice for testing because of possible language barriers, or potential cultural and religious aspects. 20, 21 More than 50 years of experience in endemic countries has shown that, in order to make this form of carrier screening more effective it is important to inform the population at risk as well as the primary care providers and to involve all in the process. Otherwise, it is known that GPs communicate less adequately with ethnic minority patients compared to the general population. 22 Furthermore, neonatal screening is a complex process, involving many people and different organizations. As with any other new process integrating this in the current practice takes time and needs close supervision and monitoring. 23 We conclude by stating that the goal of reporting carrier status for hemoglobinopathies in universal neonatal screening in the Netherlands has not been achieved in the observed period. The majority of the parents in our study was not tested for hemoplobinopathies after disclosure of the carrier status of their child. Since GPs reported few barriers in counseling parents and only indicate a lack of knowledge and limited clinical experience, more efforts are needed to provide better information to GPs and to help facilitate their work.
